Champions Oncology (CSBR) Capital Expenditures (2010 - 2026)
Champions Oncology (CSBR) recorded quarterly Capital Expenditures of $172000.0 in Q1 2026, up 847.83% quarter-over-quarter from -$23000.0 in Q4 2025, and up 26.47% on a YoY basis from $136000.0 in Q1 2025.
Champions Oncology (CSBR) Capital Expenditures (2010 - 2026) Analysis & Trends
Champions Oncology's Capital Expenditures history runs 17 years deep, the most recent figure standing at $172000.0 for Q1 2026.
- In Q1 2026, Capital Expenditures rose 26.47% year-over-year to $172000.0; the TTM figure through Jan 2026 stood at $256000.0 (up 88.24% YoY), while the FY2025 annual figure was $197000.0, changed N/A from the prior year.
- Capital Expenditures was $172000.0 for Q1 2026 at Champions Oncology, up from -$23000.0 in the prior quarter.
- In the past five years, Capital Expenditures ranged from a high of $760000.0 in Q2 2023 to a low of -$747000.0 in Q1 2024.
- Historically, Capital Expenditures has averaged $298214.3 across 5 years, with a median of $288500.0 in 2022.
- The sharpest annual moves came in 2024 and 2025: Capital Expenditures tumbled 199.07% in 2024, then surged 118.21% in 2025.
- A 5-year view of Capital Expenditures shows it stood at $604000.0 in 2022, then sank by 86.92% to $79000.0 in 2023, then sank by 1045.57% to -$747000.0 in 2024, then soared by 96.92% to -$23000.0 in 2025, then jumped by 847.83% to $172000.0 in 2026.
- The last three Capital Expenditures figures came in at $172000.0 (Q1 2026), -$23000.0 (Q4 2025), and $46000.0 (Q3 2025), per Business Quant data.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Capex (Qtr) |
|---|---|---|---|---|---|
| 1 | Alterity Therapeutics | 719,706.53 Bn | 719,706.50 Bn | - | - |
| 2 | Belite Bio | 55,800.00 Bn | 55,800.00 Bn | - | - |
| 3 | Quantum Biopharma | 18,182.30 Bn | 18,182.29 Bn | - | - |
| 4 | Legend Biotech | 3,154.00 Bn | 3,153.71 Bn | 242.10 Mn | - |
| 5 | Akari Therapeutics | 1,844.30 Bn | 1,844.29 Bn | - | - |
| 6 | Evaxion A | 1,567.96 Bn | 1,567.94 Bn | - | - |
| 7 | Psyence Biomedical | 251.43 Bn | 251.42 Bn | - | - |
| 8 | Vertex Pharmaceuticals | 112.56 Bn | 105.31 Bn | 2.59 Bn | 133.40 Mn |
| 9 | Abivax | 94.37 Bn | 94.37 Bn | - | -63,220.27 |
| 10 | Champions Oncology | 78.46 Mn | 71.46 Mn | 13.89 Mn | 172,000.00 |
Historic Data
Download Data| Date | Value |
|---|---|
| Jan 31, 2026 | 172,000.00 |
| Jan 31, 2026 | 172,000.00 |
| Oct 31, 2025 | -23,000.00 |
| Oct 31, 2025 | -23,000.00 |
| Jul 31, 2025 | 46,000.00 |
| Jul 31, 2025 | 46,000.00 |
| Apr 30, 2025 | 61,000.00 |
| Apr 30, 2025 | 61,000.00 |
| Jan 31, 2025 | 136,000.00 |
| Jan 31, 2025 | 136,000.00 |
| Jan 31, 2024 | -747,000.00 |
| Jan 31, 2024 | -747,000.00 |
| Oct 31, 2023 | 79,000.00 |
| Oct 31, 2023 | 79,000.00 |
| Jul 31, 2023 | 668,000.00 |
| Jul 31, 2023 | 668,000.00 |
| Apr 30, 2023 | 760,000.00 |
| Apr 30, 2023 | 760,000.00 |
| Jan 31, 2023 | 754,000.00 |
| Jan 31, 2023 | 754,000.00 |